Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Group",
"id" : "7750",
"meta" : {
"versionId" : "8",
"lastUpdated" : "2023-12-05T12:59:21.649Z"
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 7750</b></p><a name=\"7750\"> </a><a name=\"hc7750\"> </a><a name=\"7750-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 8; Last updated: 2023-12-05 12:59:21+0000</p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/7750\">https://fevir.net/resources/Group/7750</a></p><p><b>identifier</b>: FEvIR Object Identifier/7750</p><p><b>name</b>: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill</p><p><b>status</b>: Active</p><p><b>date</b>: 2022-01-11 17:20:56+0000</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>An enumerated group participating in a randomized trial.</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><p><b>quantity</b>: 2244</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Research Study for which this is the observed sample</span></p><p><b>value</b>: <a href=\"Citation-7636.html\">Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 305335007}\">Admission to establishment (procedure)</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 32485007}\">Hospital admission</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Hospitalized</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 64572001}\">Disease (disorder)</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 840539006}\">ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>COVID-19</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 246112005}\">Severity</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 442452003}\">severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)</span></p><p><b>exclude</b>: true</p><p><b>description</b>: </p><div><p>not critically ill</p>\n</div></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750."
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
}
],
"url" : "https://fevir.net/resources/Group/7750",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "7750",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"name" : "Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill",
"status" : "active",
"date" : "2022-01-11T17:20:56.687Z",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "An enumerated group participating in a randomized trial.",
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"type" : "person",
"membership" : "enumerated",
"quantity" : 2244,
"combinationMethod" : "all-of",
"characteristic" : [
{
"code" : {
"text" : "Research Study for which this is the observed sample"
},
"valueReference" : {
🔗 "reference" : "Citation/7636",
"display" : "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911."
},
"exclude" : false,
"description" : "Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "305335007",
"display" : "Admission to establishment (procedure)"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "32485007",
"display" : "Hospital admission"
}
]
},
"exclude" : false,
"description" : "Hospitalized"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "64572001",
"display" : "Disease (disorder)"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "840539006",
"display" : "Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)"
}
],
"text" : "ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19."
},
"exclude" : false,
"description" : "COVID-19"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "246112005",
"display" : "Severity"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "442452003",
"display" : "Life threatening severity"
}
],
"text" : "severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)"
},
"exclude" : true,
"description" : "not critically ill"
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change